Navigation Links
Results of the PROFI study reported at TCT 2011
Date:11/11/2011

SAN FRANCISCO, CA NOVEMBER 11, 2011 Results from the PROFI study indicate that the use of a proximal balloon occlusion in carotid artery stenting lead to fewer cerebral ischemic lesions a predictor of stroke than with the use of a filter. Trial results were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Previous randomized trials have revealed a higher rate of stroke following carotid artery stenting when compared to surgical removal of plaque from the carotid artery. One of the reasons for this may be that the use of filters in carotid artery stenting allows plaque particles to travel to the brain. PROFI is the first randomized trial comparing proximal balloon occlusion with filter protection in patients undergoing carotid artery stenting

In the PROFI (Prevention of Cerebral Embolization by PROximal Balloon Occlusion Compared to FIlter Protection During Carotid Artery Stenting) trial, 62 patients undergoing carotid artery stenting with cerebral embolic protection for a ≥ 60 % symptomatic or ≥ 80% asymptomatic internal carotid artery stenosis were randomly assigned to proximal balloon occlusion or filter protection. The primary endpoint was the incidence of new cerebral ischemic lesions as assessed by diffusion weighted magnetic resonance imaging (DW-MRI). Secondary endpoints were the number and volume of new ischemic lesions and major adverse cardiovascular and cerebral events (MACCE).

The incidence rate of new cerebral ischemic lesions was 87.1%in the filter group, and 45.2% in the balloon group. The mean number of new cerebral ischemic lesions was 3.5 in the filter group and 1.0 in the balloon group. There were no significant differences in MACCE at 30 days between the two groups.

"In this single center, randomized trial in patients undergoing carotid artery stenting, the incidence, number, and volume of new cerebral ischemic lesions were significantly lower under proximal balloon protection than under filter protection," said Joachim Schofer, MD, Professor of Medicine, at the Medical Care Center, Professor Mathey, Professor Schofer, Hamburg University Cardiovascular Center.

"A larger randomized trial with clinical endpoints is needed to investigate whether this benefit translates into a reduced periprocedural stroke rate," said Dr. Schofer.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the EVOLVE trial reported at TCT 2011
2. Results of the REMEDEE trial reported at TCT 2011
3. Results of the NEXT clinical trial Reported at TCT 2011
4. Results of the PEPCAD-DES trial reported at TCT 2011
5. Results of the STACCATO Trial reported at TCT 2011
6. Results of the DEB-AMI Trial reported at TCT 2011
7. Results of the RIFLE STEACS clinical trial reported at TCT 2011
8. Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011
9. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
10. Combination epigenetic therapy clinical trial results
11. Results of the PARIS registry Reported at TCT 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... management software and services, is proud to announce it has joined the National ... association representing the interests of chronically ill, disabled, and dying Americans of all ...
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, the ... launch of a free, public-facing tool for analyzing the costs of various drug ... provide comparative information to patients, providers, insurers and pharmaceutical companies about the estimated ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, a leading ... Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up ... association with efforts by the American College of Surgeons, U.S. Department of Defense, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of warmer weather ... those self-conscious about a double chin, this means more anxiety than elation. The cosmetic ... “For most people, a double chin is undesirable,” Dr. Goldman said, “but it seems ...
(Date:3/28/2017)... ... 28, 2017 , ... Calibration, qualification, and the appropriate level ... maintaining GMP and USP compliance. In a new webinar from METTLER TOLEDO entitled ... these requirements are explained. The challenge is to determine how to put ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Neurim Pharmaceuticals ("Neurim") and Exeltis announced today ... for Neurim,s new Rx PedPRM in Spain . ... Neurim,s paediatric prolonged-release ... children with Autism Spectrum Disorders (ASD) and neurogenetic diseases. It is ... The collaboration with Exeltis will help increase the accessibility of ...
(Date:3/29/2017)... FinancialBuzz.com News Commentary  ... The U.S. could see significant economic benefits from the expanding ... Frontier Data, the legal cannabis market is projected to create 283,422 ... the United States , as well as the economic ... that drives growth in this sector. Medical cannabis is now legal ...
(Date:3/28/2017)... LONDON , March 28, 2017 The ... at a CAGR of 13.45% from 2016 to 2023 ... Description Cancer is a chronic disease ... emerging in the cancer diagnostics market. This report is ... tumor test. The market growth is propelled due to ...
Breaking Medicine Technology: